These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 32065006

  • 1. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG, Henze T, Essner U, Trompke C, Vila Silván C.
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [Abstract] [Full Text] [Related]

  • 2. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.
    Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C.
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [Abstract] [Full Text] [Related]

  • 3. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.
    Marková J.
    Neurodegener Dis Manag; 2019 Apr; 9(2s):9-13. PubMed ID: 30657024
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis.
    Bethoux FA, Farrell R, Checketts D, Sahr N, Berwaerts J, Alexander JK, Skobieranda F.
    Mult Scler Relat Disord; 2024 Sep; 89():105740. PubMed ID: 39106541
    [Abstract] [Full Text] [Related]

  • 5. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J.
    Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
    [Abstract] [Full Text] [Related]

  • 6. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L.
    Eur Neurol; 2016 Jun; 75(5-6):236-43. PubMed ID: 27160412
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
    D'hooghe M, Willekens B, Delvaux V, D'haeseleer M, Guillaume D, Laureys G, Nagels G, Vanderdonckt P, Van Pesch V, Popescu V.
    BMC Neurol; 2021 Jun 22; 21(1):227. PubMed ID: 34157999
    [Abstract] [Full Text] [Related]

  • 10. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
    Paolicelli D, Direnzo V, Manni A, D'Onghia M, Tortorella C, Zoccolella S, Di Lecce V, Iaffaldano A, Trojano M.
    J Clin Pharmacol; 2016 Jul 22; 56(7):845-51. PubMed ID: 26608223
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S.
    J Neurol; 2013 Apr 22; 260(4):984-97. PubMed ID: 23180178
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
    Di Marzo V, Centonze D.
    CNS Neurosci Ther; 2015 Mar 22; 21(3):215-21. PubMed ID: 25475413
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
    Ziemssen T.
    Neurodegener Dis Manag; 2019 Apr 22; 9(2s):1-2. PubMed ID: 30657019
    [Abstract] [Full Text] [Related]

  • 17. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
    Flachenecker P, Henze T, Zettl UK.
    Eur Neurol; 2014 Apr 22; 72(1-2):95-102. PubMed ID: 24943098
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M, Mancinelli L, Perrone A, Sabattini L, Mohamed S, Scandellari C, Foschi M, Vacchiano V, Lugaresi A, Riva R.
    Clin Neuropharmacol; 2018 Apr 22; 41(5):171-176. PubMed ID: 30024443
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    Trojano M, Vila C.
    Eur Neurol; 2015 Apr 22; 74(3-4):178-85. PubMed ID: 26571097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.